This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

Cannabis-induced psychosis: how does it evolve over time? Annual incidence, transition to schizophrenia, and mortality

Cannabis-induced psychosis: how do they fare over time? on annual incidence, transition to schizophrenia and mortality

The incidence of cannabis-induced psychosis in Scandinavian countries has increased substantially since the 2000s, and the condition is associated with high mortality, particularly a high risk of suicide, and a transition rate to schizophrenia of up to 36% within six years.

The study aimed to examine the annual incidence of cannabis-induced psychosis (CIP), its association with mortality, and the rate of transition to schizophrenia. Registry data covering the entire adult populations of Denmark, Norway, and Sweden were used to estimate annual CIP incidence rates per 100,000 people between 2000 and 2016 and to examine the association between CIP and all-cause and cause-specific mortality; a smaller analysis based solely on Norwegian data calculated cumulative rates of transition from CIP to schizophrenia spectrum disorder. From 2000 to 2016, annual incidence rates increased from 2.6 to 5.6 in Denmark and from 0.8 to 2.7 in Sweden, corresponding to increases of 115% and 238%, respectively. In Norway, the incidence rate rose from 1.8 to 3.0 between 2010 and 2015, an increase of 67%. Across the three countries, the pooled hazard ratio for all-cause mortality following CIP was HR=7.32 (95% confidence interval, CI 6.34–8.44); the largest increase in cause-specific mortality was observed for suicide (HR=15.31; 95% CI 10.99–21.33). The six-year cumulative rate of transition from CIP to schizophrenia spectrum disorder was 36% (95% CI 31.4–41.0). The authors emphasize that CIP incidence has increased over time and that the condition is associated with substantially elevated mortality and a high rate of subsequent schizophrenia diagnosis, identifying a severely disadvantaged patient group requiring research, prevention, and treatment efforts.

Tüm WCP 2026 özetleri